Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies

Abstract Introduction Standard therapy for patients with mild to moderate atopic dermatitis (AD) typically includes topical therapies; however, patients with more extensive AD and/or AD refractory to topical therapy may benefit from systemic treatment. Ruxolitinib cream monotherapy has demonstrated...

Descrición completa

Detalles Bibliográficos

Principais autores:	Eric L. Simpson, Leon Kircik, Andrew Blauvelt, Howard Kallender, Daniel Sturm, Mingyue Wang, Lawrence F. Eichenfield
Formato:	Artigo
Idioma:	Inglês
Publicado:	Adis, Springer Healthcare 2024-07-01
Series:	Dermatology and Therapy
Assuntos:	Atopic dermatitis Ruxolitinib cream Janus kinase inhibition JAK
Acceso en liña:	https://doi.org/10.1007/s13555-024-01219-8
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!